A comparison of the bioavailability of two carbamazepine preparations (200 and 400 mg tablets)

Abstract

A 2-week open, randomized, crossover study was conducted in epileptic patients on chronic therapy, who took either carbamazepine (CBZ) 200 or CBZ 400 mg tablets. The oral dose was 1200 or 1600 mg/day, according to individual needs. There was no difference in absorption or steady-state levels between the two preparations. The new galenic preparation of CBZ will help the neurologist to reduce the number of tablets taken by severe epileptic patients, with no risk but only benefits for the subjects.